Literature DB >> 21884820

Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas.

Yongji Tian1, Benjamin E Rich, Natalie Vena, Justin M Craig, Laura E Macconaill, Veena Rajaram, Stewart Goldman, Hala Taha, Madeha Mahmoud, Memet Ozek, Aydin Sav, Janina A Longtine, Neal I Lindeman, Levi A Garraway, Azra H Ligon, Charles D Stiles, Sandro Santagata, Jennifer A Chan, Mark W Kieran, Keith L Ligon.   

Abstract

Alterations of BRAF are the most common known genetic aberrations in pediatric gliomas. They frequently are found in pilocytic astrocytomas, where genomic duplications involving BRAF and the poorly characterized gene KIAA1549 create fusion proteins with constitutive B-Raf kinase activity. BRAF V600E point mutations are less common and generally occur in nonpilocytic tumors. The development of BRAF inhibitors as drugs has created an urgent need for robust clinical assays to identify activating lesions in BRAF. KIAA1549-BRAF fusion transcripts have been detected in frozen tissue, however, methods for FFPE tissue have not been reported. We developed a panel of FFPE-compatible quantitative RT-PCR assays for the most common KIAA1549-BRAF fusion transcripts. Application of these assays to a collection of 51 low-grade pediatric gliomas showed 97% sensitivity and 91% specificity compared with fluorescence in situ hybridization or array comparative genomic hybridization. In parallel, we assayed samples for the presence of the BRAF V600E mutation by PCR pyrosequencing. The data further support previous observations that these two alterations of the BRAF, KIAA1549 fusions and V600E point mutations, are associated primarily with pilocytic astrocytomas and nonpilocytic gliomas, respectively. These results show that fusion transcripts and mutations can be detected reliably in standard FFPE specimens and may be useful for incorporation into future studies of pediatric gliomas in basic science or clinical trials.
Copyright © 2011 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21884820      PMCID: PMC3194058          DOI: 10.1016/j.jmoldx.2011.07.002

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  22 in total

Review 1.  New insight into BRAF mutations in cancer.

Authors:  Nathalie Dhomen; Richard Marais
Journal:  Curr Opin Genet Dev       Date:  2007-02       Impact factor: 5.578

2.  Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program.

Authors:  E Anders Kolb; Richard Gorlick; Peter J Houghton; Christopher L Morton; Geoffrey Neale; Stephen T Keir; Hernan Carol; Richard Lock; Doris Phelps; Min H Kang; C Patrick Reynolds; John M Maris; Catherine Billups; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2010-10       Impact factor: 3.167

3.  Detection of specific polymerase chain reaction product by utilizing the 5'----3' exonuclease activity of Thermus aquaticus DNA polymerase.

Authors:  P M Holland; R D Abramson; R Watson; D H Gelfand
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

4.  Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas.

Authors:  Joshua D Schiffman; J Graeme Hodgson; Scott R VandenBerg; Patrick Flaherty; Mei-Yin C Polley; Mamie Yu; Paul G Fisher; David H Rowitch; James M Ford; Mitchel S Berger; Hanlee Ji; David H Gutmann; C David James
Journal:  Cancer Res       Date:  2010-01-12       Impact factor: 12.701

5.  Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene.

Authors:  Angela J Sievert; Eric M Jackson; Xiaowu Gai; Hakon Hakonarson; Alexander R Judkins; Adam C Resnick; Leslie N Sutton; Phillip B Storm; Tamim H Shaikh; Jaclyn A Biegel
Journal:  Brain Pathol       Date:  2008-10-21       Impact factor: 6.508

6.  Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma.

Authors:  D T W Jones; S Kocialkowski; L Liu; D M Pearson; K Ichimura; V P Collins
Journal:  Oncogene       Date:  2009-04-13       Impact factor: 9.867

7.  BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas.

Authors:  Stefan Pfister; Wibke G Janzarik; Marc Remke; Aurélie Ernst; Wiebke Werft; Natalia Becker; Grischa Toedt; Andrea Wittmann; Christian Kratz; Heike Olbrich; Rezvan Ahmadi; Barbara Thieme; Stefan Joos; Bernhard Radlwimmer; Andreas Kulozik; Torsten Pietsch; Christel Herold-Mende; Astrid Gnekow; Guido Reifenberger; Andrey Korshunov; Wolfram Scheurlen; Heymut Omran; Peter Lichter
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

8.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

9.  BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications.

Authors:  Dora Dias-Santagata; Quynh Lam; Kathy Vernovsky; Natalie Vena; Jochen K Lennerz; Darrell R Borger; Tracy T Batchelor; Keith L Ligon; A John Iafrate; Azra H Ligon; David N Louis; Sandro Santagata
Journal:  PLoS One       Date:  2011-03-29       Impact factor: 3.240

10.  Profiling critical cancer gene mutations in clinical tumor samples.

Authors:  Laura E MacConaill; Catarina D Campbell; Sarah M Kehoe; Adam J Bass; Charles Hatton; Lili Niu; Matt Davis; Keluo Yao; Megan Hanna; Chandrani Mondal; Lauren Luongo; Caroline M Emery; Alissa C Baker; Juliet Philips; Deborah J Goff; Michelangelo Fiorentino; Mark A Rubin; Kornelia Polyak; Jennifer Chan; Yuexiang Wang; Jonathan A Fletcher; Sandro Santagata; Gianni Corso; Franco Roviello; Ramesh Shivdasani; Mark W Kieran; Keith L Ligon; Charles D Stiles; William C Hahn; Matthew L Meyerson; Levi A Garraway
Journal:  PLoS One       Date:  2009-11-18       Impact factor: 3.240

View more
  39 in total

1.  BRAF-V600E mutation in pediatric and adult glioblastoma.

Authors:  Sonika Dahiya; Ryan J Emnett; Devon H Haydon; Jeffrey R Leonard; Joanna J Phillips; Arie Perry; David H Gutmann
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

2.  Pilocytic astrocytomas: BRAFV600E and BRAF fusion expression patterns in pediatric and adult age groups.

Authors:  Hetakshi Kurani; Mamta Gurav; Omshree Shetty; Girish Chinnaswamy; Aliasagar Moiyadi; Tejpal Gupta; Rakesh Jalali; Sridhar Epari
Journal:  Childs Nerv Syst       Date:  2019-07-18       Impact factor: 1.475

3.  Multilineage ACTB mutation in a patient with fibro-osseous maxillary lesion and pilocytic astrocytoma.

Authors:  Young H Lim; Andrea B Burke; Mary S Roberts; Michael T Collins; Keith A Choate
Journal:  Am J Med Genet A       Date:  2018-08-27       Impact factor: 2.802

Review 4.  To BRAF or not to BRAF: is that even a question anymore?

Authors:  Craig Horbinski
Journal:  J Neuropathol Exp Neurol       Date:  2013-01       Impact factor: 3.685

5.  Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype.

Authors:  Guillaume Bergthold; Pratiti Bandopadhayay; Yujin Hoshida; Shakti Ramkissoon; Lori Ramkissoon; Benjamin Rich; Cecile L Maire; Brenton R Paolella; Steven E Schumacher; Barbara Tabak; Ruben Ferrer-Luna; Memet Ozek; Aydin Sav; Sandro Santagata; Patrick Yung Wen; Liliana C Goumnerova; Azra H Ligon; Charles Stiles; Rosalind Segal; Todd Golub; Jacques Grill; Keith L Ligon; Jennifer A Chan; Mark W Kieran; Rameen Beroukhim
Journal:  Neuro Oncol       Date:  2015-03-29       Impact factor: 12.300

Review 6.  Molecular markers of glioma: an update on recent progress and perspectives.

Authors:  Kirti Gupta; Pravin Salunke
Journal:  J Cancer Res Clin Oncol       Date:  2012-10-06       Impact factor: 4.553

7.  History and current state of pediatric neurosurgery at Beijing Tiantan Hospital Neurosurgery Center.

Authors:  Wei Liu; Jie Tang; Nicholas Van Halm-Lutterodt; Shiqi Luo; Chunde Li
Journal:  Childs Nerv Syst       Date:  2018-03-08       Impact factor: 1.475

8.  Pilocytic astrocytoma with anaplastic features presenting good long-term clinical course after surgery alone: a case report.

Authors:  Katsuya Saito; Masahiro Toda; Kazunari Yoshida
Journal:  Childs Nerv Syst       Date:  2014-08-07       Impact factor: 1.475

9.  Something old and something new about molecular diagnostics in gliomas.

Authors:  Craig Horbinski
Journal:  Surg Pathol Clin       Date:  2012-12-01

10.  BRAF alterations in pediatric low grade gliomas and mixed neuronal-glial tumors.

Authors:  Efthymios Dimitriadis; George A Alexiou; Panagiota Tsotsou; Efthymia Simeonidi; Kalliopi Stefanaki; Amalia Patereli; Neofytos Prodromou; Nikolaos Pandis
Journal:  J Neurooncol       Date:  2013-04-24       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.